SML2075
Gimeracil
≥98% (HPLC)
Synonym(s):
5-Chloropyridine-2,4-diol, 5-chloro-4-hydroxypyridin-2(1H)-one, CDHP, Gimestat
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C5H4ClNO2
CAS Number:
Molecular Weight:
145.54
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77
Recommended Products
![(1R,8S,9s)-Bicyclo[6.1.0]non-4-yn-9-ylmethyl N-succinimidyl carbonate for Copper-free Click Chemistry](/deepweb/assets/sigmaaldrich/product/structures/969/022/d6776082-2f7a-47c7-bcd4-3830dac0fb7d/640/d6776082-2f7a-47c7-bcd4-3830dac0fb7d.png)
Assay
≥98% (HPLC)
form
powder
color
white to brown
solubility
DMSO: 2 mg/mL, clear
storage temp.
−20°C
InChI
1S/C5H4ClNO2/c6-3-2-7-5(9)1-4(3)8/h1-2H,(H2,7,8,9)
InChI key
ZPLQIPFOCGIIHV-UHFFFAOYSA-N
Biochem/physiol Actions
Gimeracil (5-chloro-2, 4-dihydroxypyridine) is an orally active inhibitor against dihydropyrimidine dehydrogenase (DPYD), which degrades pyrimidine and the chemotherapeutic drug 5-fluorouracil (5FU). Gimeracil is shown to exhibit cancer-radiosensitizing efficacy in cultures in vitro (1 mM) and in mice in vivo (2.5-25 mg/kg, p.o.) in a DPYD-dependent manner via partial suppression of DNA repair by homologous recombination (HR).
Signal Word
Warning
Hazard Statements
Precautionary Statements
Hazard Classifications
Acute Tox. 4 Oral
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Choose from one of the most recent versions:
Certificates of Analysis (COA)
Lot/Batch Number
Sorry, we don't have COAs for this product available online at this time.
If you need assistance, please contact Customer Support.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Keiji Koda et al.
Anticancer research, 36(10), 5325-5331 (2016-11-01)
It has not been elucidated whether the clinical efficacy of oral fluoropyrimidines for adjuvant chemotherapy of colorectal cancer varies with tumor biological characteristics. A multicenter randomized trial was performed comparing oral tegafur/gimeracil/oteracil (S-1) and uracil-tegafur/ leucovorin (UFT/LV) as adjuvant therapy
Masakazu Fukushima et al.
Oncology reports, 24(5), 1307-1313 (2010-09-30)
Chemoradiotherapy is a useful treatment strategy in patients with locally advanced cancers. In particular, combination of 5-fluorouracil (5-FU) with X-ray irradiation is effective for the treatment of some types of gastrointestinal cancers. We investigated the antitumor effects of combination treatment
T Wang et al.
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 20(3), 181-186 (2016-04-14)
This study evaluated the efficacy and safety of the combination drug tegafur, gimeracil, and oteracil potassium (S-1) concurrent with 3-dimensional conformal radiotherapy for newly diagnosed squamous cell carcinoma of the lung in elderly patients. Patients with pathologically or cytologically newly
Ryohei Nishiguchi et al.
BMJ case reports, 2016 (2016-12-10)
The most common histological classification of bile duct cancer is adenocarcinoma and squamous cell carcinoma (SCC) is relatively rare. We report a case of a 78-year-old man with SCC of the extrahepatic bile duct associated with metachronous para-aortic lymph node
Koh-Ichi Sakata et al.
Cancer science, 102(9), 1712-1716 (2011-06-15)
Gimeracil (5-chloro-2, 4-dihydroxypyridine) is an inhibitor of dihydropyrimidine dehydrogenase (DPYD), which degrades pyrimidine including 5-fluorouracil in the blood. Gimeracil was originally added to an oral fluoropyrimidine derivative S-1 to yield prolonged 5-fluorouracil concentrations in serum and tumor tissues. We have
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service